{"id":"abiraterone-acetate-or-enzalutamide","safety":{"commonSideEffects":[{"rate":"30–40","effect":"Hypertension"},{"rate":"15–20","effect":"Hypokalemia"},{"rate":"30–40","effect":"Fatigue"},{"rate":"20–30","effect":"Hot flashes"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"0.5–1","effect":"Seizures (enzalutamide)"},{"rate":"5–10","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abiraterone acetate is a prodrug that inhibits 17α-hydroxylase/17,20-lyase (CYP17A1), a key enzyme in testosterone and DHT synthesis, thereby depleting intratumoral androgens. Enzalutamide is an androgen receptor antagonist that blocks AR signaling downstream. Together or individually, these agents suppress the androgen axis critical for castration-resistant prostate cancer (CRPC) progression.","oneSentence":"Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, both reducing androgen-driven prostate cancer growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:41.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"},{"name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)"}]},"trialDetails":[{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06457919","phase":"PHASE1, PHASE2","title":"A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT04221542","phase":"PHASE1","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2020-03-04","conditions":"Prostate Cancer","enrollment":479},{"nctId":"NCT06551324","phase":"PHASE3","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-10-21","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":600},{"nctId":"NCT06632977","phase":"PHASE2","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-06","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":474},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":"Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":100},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":"Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer","enrollment":277},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":"Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer","enrollment":174},{"nctId":"NCT06764485","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":960},{"nctId":"NCT06120491","phase":"PHASE3","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-21","conditions":"Metastatic Castration-Sensitive Prostate Cancer","enrollment":1800},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06072196","phase":"","title":"A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-10-04","conditions":"Prostatic Neoplasms","enrollment":3017},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT02960022","phase":"PHASE2","title":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-12-22","conditions":"Prostate Cancer","enrollment":900},{"nctId":"NCT05367440","phase":"PHASE1, PHASE2","title":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-02","conditions":"Metastatic Prostate Cancer","enrollment":174},{"nctId":"NCT07181122","phase":"","title":"Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Ankara Etlik City Hospital","startDate":"2025-10-22","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":102},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT06844383","phase":"PHASE2","title":"A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate","status":"RECRUITING","sponsor":"Prostate Cancer Clinical Trials Consortium","startDate":"2025-10","conditions":"Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":126},{"nctId":"NCT06141993","phase":"","title":"ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials","status":"RECRUITING","sponsor":"Duke University","startDate":"2024-05-13","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic","enrollment":120},{"nctId":"NCT07198633","phase":"PHASE1, PHASE2","title":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-10","conditions":"Advanced Prostate Cancer","enrollment":212},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT05588609","phase":"PHASE2","title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","status":"TERMINATED","sponsor":"Merus B.V.","startDate":"2022-11-17","conditions":"NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer","enrollment":13},{"nctId":"NCT06687421","phase":"","title":"Implementation of Precision Medicine in High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Andreas Josefsson","startDate":"2024-06-10","conditions":"Prostate Cancer","enrollment":5500},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT05413421","phase":"PHASE1","title":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"ORIC Pharmaceuticals","startDate":"2022-06-01","conditions":"Metastatic Prostate Cancer","enrollment":250},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT02975934","phase":"PHASE3","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-06-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":405},{"nctId":"NCT06151418","phase":"","title":"A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-22","conditions":"Prostatic Neoplasms","enrollment":2313},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT04262154","phase":"PHASE2","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-03","conditions":"Metastatic Prostate Cancer","enrollment":28},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT06652607","phase":"","title":"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-12-20","conditions":"Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer","enrollment":152},{"nctId":"NCT06838520","phase":"","title":"Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":200},{"nctId":"NCT02663193","phase":"","title":"Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":108},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":93},{"nctId":"NCT03002220","phase":"PHASE2","title":"Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status","status":"COMPLETED","sponsor":"MedSIR","startDate":"2016-12-21","conditions":"Prostate Cancer","enrollment":52},{"nctId":"NCT02116582","phase":"PHASE4","title":"A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-05-23","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":215},{"nctId":"NCT05393791","phase":"PHASE2","title":"Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-11-10","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":168},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT06473259","phase":"","title":"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","status":"RECRUITING","sponsor":"Santa Chiara Hospital","startDate":"2016-12-16","conditions":"Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Tumor","enrollment":3000},{"nctId":"NCT06204302","phase":"","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-01-05","conditions":"Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer","enrollment":1800},{"nctId":"NCT03148795","phase":"PHASE2","title":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-04","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT03554317","phase":"PHASE2","title":"COMbination of Bipolar Androgen Therapy and Nivolumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-05","conditions":"Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer","enrollment":45},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":"Metastatic Castration-sensitive Prostate Cancer","enrollment":960},{"nctId":"NCT04844749","phase":"PHASE3","title":"Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer","enrollment":105},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT03999515","phase":"PHASE2","title":"Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-04-27","conditions":"Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":3},{"nctId":"NCT04495179","phase":"PHASE2","title":"A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-04","conditions":"Progressive Metastatic Castrate-Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT04139772","phase":"PHASE3","title":"Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-09-01","conditions":"Metastatic Castration-resistent Prostate Cancer","enrollment":18},{"nctId":"NCT05245435","phase":"NA","title":"Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2022-04","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT05422911","phase":"PHASE2","title":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2022-06-30","conditions":"Metastatic Cancer, Neoplasm, Prostate","enrollment":200},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT02268175","phase":"PHASE2","title":"Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":"Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer","enrollment":75},{"nctId":"NCT05212857","phase":"PHASE2","title":"Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-04","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT03551782","phase":"PHASE1","title":"A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-06-28","conditions":"Castration-Resistant Prostatic Neoplasms","enrollment":33},{"nctId":"NCT02353715","phase":"","title":"Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-07-07","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT02125357","phase":"PHASE2","title":"Sequencing Abiraterone and Enzalutamide in mCRPC","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2014-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":202},{"nctId":"NCT01946165","phase":"PHASE2","title":"Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-31","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":"Prostatic Neoplasms","enrollment":68},{"nctId":"NCT02456571","phase":"","title":"CTC Immune Checkpoint","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Prostate Cancer","enrollment":38},{"nctId":"NCT02379390","phase":"PHASE2","title":"Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-06-17","conditions":"Prostate Cancer Metastatic","enrollment":8},{"nctId":"NCT03325127","phase":"","title":"Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2017-10-30","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":""},{"nctId":"NCT02215161","phase":"PHASE2","title":"Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-09-02","conditions":"Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":14},{"nctId":"NCT02254785","phase":"PHASE2","title":"Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2014-10","conditions":"Metastatic Castration-Resistant Prostatic Cancer","enrollment":120},{"nctId":"NCT01981707","phase":"PHASE2, PHASE3","title":"F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2013-12","conditions":"Castration-resistant Prostate Cancer","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5001,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abiraterone Acetate or Enzalutamide","genericName":"Abiraterone Acetate or Enzalutamide","companyName":"National Cancer Institute, Naples","companyId":"national-cancer-institute-naples","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, both reducing androgen-driven prostate cancer growth. Used for Metastatic castration-resistant prostate cancer (mCRPC), Non-metastatic castration-resistant prostate cancer (nmCRPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}